Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus

  1. Celia Peralesa,b
  1. aCentro de Biología Molecular Severo Ochoa (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
  2. bCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Barcelona, Spain
  3. cLiver Unit, Internal Medicine Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
  4. dRoche Diagnostics, S.L., Sant Cugat del Valles, Spain
  5. eUniversitat Autonoma de Barcelona, Barcelona, Spain
  6. fCenter for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, Rockefeller University, New York, New York, USA
  1. M. S. Diamond, Editor

ABSTRACT

Passage of hepatitis C virus (HCV) in human hepatoma cells resulted in populations that displayed partial resistance to alpha interferon (IFN-α), telaprevir, daclatasvir, cyclosporine, and ribavirin, despite no prior exposure to these drugs. Mutant spectrum analyses and kinetics of virus production in the absence and presence of drugs indicate that resistance is not due to the presence of drug resistance mutations in the mutant spectrum of the initial or passaged populations but to increased replicative fitness acquired during passage. Fitness increases did not alter host factors that lead to shutoff of general host cell protein synthesis and preferential translation of HCV RNA. The results imply that viral replicative fitness is a mechanism of multidrug resistance in HCV.

IMPORTANCE Viral drug resistance is usually attributed to the presence of amino acid substitutions in the protein targeted by the drug. In the present study with HCV, we show that high viral replicative fitness can confer a general drug resistance phenotype to the virus. The results exclude the possibility that genomes with drug resistance mutations are responsible for the observed phenotype. The fact that replicative fitness can be a determinant of multidrug resistance may explain why the virus is less sensitive to drug treatments in prolonged chronic HCV infections that favor increases in replicative fitness.

FOOTNOTES

    • Received 26 June 2014.
    • Accepted 31 July 2014.
  • Address correspondence to Esteban Domingo, edomingo{at}cbm.uam.es, or Celia Perales, cperales{at}cbm.uam.es.
  • * Present address: Julie Sheldon, Institute of Experimental Virology, Twincore Centre for Experimental and Clinical Infection Research, Hannover, Germany.

  • Published ahead of print 13 August 2014

  • Dedicated to John J. Holland (1929-2013).

| Table of Contents